A phase II study of Bevacizumab combined with Carboplatin and Weekly Paclitaxel for Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer. North Japan Lung Cancer Study Group Trial 1002
- Conditions
- non-squamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000003949
- Lead Sponsor
- Miyagi Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1) Clinically active interstitial pneumonia or pulmonary fibrosis, detectable on CT scan. 2) Uncontrollable pleural or pericardial effusion or ascites. 3) Current or previous hemoptysis (>=1 teaspoon). 4) Brain metastasis. 5) Tumor invading thoracic major vessel. 6) Tumor with cavity. 7) Severe co-morbidities (ex. uncontrolled heart or lung or hepatic or renal disease or diabetes). 8) Regular use of corticosteroid (less than 2 weeks interval after cessation). 9) Active gastrointestinal ulcer. 10) Peripheral sensory neuropathy >= Grade 2. 11) Pregnancy or lactation, or those who decline contraception. 12) Hypersensitivity of Taxans or alcohol and the medicine made of the polio castor oil content. 13) Active concomitant malignancy. Except carcinoma in situ or those who did not relapse 5-years or more. 14) Contraindication with carboplatin or paclitaxel or bevacizumab. 15) Those judged to be not suitable by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method